[Federal Register Volume 80, Number 16 (Monday, January 26, 2015)]
[Notices]
[Page 3979]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-01313]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Halo
Pharmaceutical, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before March 27, 2015.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152. Request for
hearings should be sent to: Drug Enforcement Administration, Attention:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the
Controlled Substances Act to the Administrator of the Drug Enforcement
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all
necessary functions with respect to the promulgation and implementation
of 21 CFR part 1301, incident to the registration of manufacturers,
distributors, and dispensers, of controlled substances (other than
final orders in connection with suspension, denial, or revocation of
registration) has been redelegated to the Deputy Assistant
Administrator of the DEA Office of Diversion Control (``Deputy
Assistant Administrator'') pursuant to section 7 of 28 CFR pt. 0,
subpt. R, App.
In accordance with 21 CFR 1301.33(a), this is notice that on July
21, 2014, Halo Pharmaceutical, Inc., 30 North Jefferson Road, Whippany,
New Jersey 07981, applied to be registered as a bulk manufacturer of
the following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to manufacture Hydromorphone HCl for sale to
other manufacturers and to manufacture other controlled substances for
distribution to its customers. Dihydromorphine is an intermediate in
the manufacture of Hydromorphone and is not for commercial
distribution.
Dated: January 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-01313 Filed 1-23-15; 8:45 am]
BILLING CODE P